Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
Medical Affairs describes itself as a third strategic pillar in the biopharmaceutical and MedTech industries alongside R&D and Commercial. But is this truly the case or is Medical Affairs' strategic role still aspirational? And if it is in some ways aspirational, what does Medical Affairs need to do in order to truly achieve its position alongside R&D and Commercial? Here, three Medical Affairs leaders discuss these questions and offer their perspective for the future of the function.
Precision Value & Health partners with life science companies to establish and communicate the clinical, economic, and humanistic value of innovative therapies.
In this white paper, MedComms, Field Medical and Insights Focus Area Working Groups (FAWGs) demonstrate the value of and elucidate best practices for an insights-driven collaborative approach to creating an iMC S/P.
We partner with our clients to turn science into value by helping them understand the potential of their molecules, shaping their strategic plans and allowing their decision making to be the biggest differentiating factor in the success of their products.
It can be challenging to remember to log into each of the systems consistently enough to remain aware of information that allows you to be best prepared for engagements, identify new opportunities to engage, and discover KOL insights. The best way to make sure you are getting the maximum impact on the data and systems you have available to you is to set up automated alerts.
PwC partners with our clients to identify the scope of each company’s needs, and support Medical Affairs through the transformation journey.
Insights management is widely acknowledged across the pharmaceutical industry as being pivotal for informing and influencing strategy. Despite this, companies approach insights gathering in a fragmented and inefficient manner, with a lack of consistent frameworks. The risk is a loss of strategic advantage due to information being synthesized too slowly, and decisions being made on old or incomplete data.
Should teams be focussing on people, processes or technology when considering how to improve their insights gathering? The key to developing a robust insights gathering approach is striking the right balance between all three. Join this webinar to understand key steps that all Medical Affairs teams can take now to move towards a more holistic approach to insights gathering activities, allowing them to make better, faster decisions.
This webinar will address:
MAPS is excited to announce the appointment of Tamas Koncz, MD, MSc, PhD, Chief Medical Officer for the Inflammation and Immunology Business at Pfizer, to the MAPS Board of Directors.
Real Chemistry’s mission is to transform what healthcare is to what it should be by leveraging the industry’s most advanced AI-powered insights, diverse expertise and customer-centric ideas.
This podcast addresses two important categories of Digital Opinion Leaders (DOLs) we should all be listening to.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.